Duloxetine
Product Images NDC 70954-860

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 15 technical images submitted to the FDA as part of the official labeling for Duloxetine (NDC 70954-860). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Ani Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Fig-3 (Fig 3)

Fig-3 (Fig 3)
This text provides information on the percentage of patients improved with different dosages of duloxetine and placebo in terms of pain improvement from baseline. The percentages range from 0 to 100% across different dosage groups for duloxetine (60mg BID, 60mg QD, 20mg QD) and placebo.*
FDA Label Image

Figure-8 (Figure Eight)

Figure-8 (Figure Eight)
This text provides data on the percentage of patients improved with a placebo compared to Duloxetine 60-120 mg once daily. It includes a graph showing the percent improvement in pain from baseline.*
FDA Label Image

Figure-5 (Figure Five)

Figure-5 (Figure Five)
This text contains a description about the percent improvement in Pain from Baseline. It seems to be related to a report or analysis on pain management or a similar subject matter.*
FDA Label Image

Figure-4 (Figure Four)

Figure-4 (Figure Four)
FDA Label Image

Figure-9 (Figure Nine)

Figure-9 (Figure Nine)
FDA Label Image

Figure-1 (Figure One)

Figure-1 (Figure One)
This data chart shows the proportion of patients experiencing a relapse over time (in days) for individuals taking a placebo compared to those taking Duloxetine. The x-axis represents time from randomization to relapse in days, while the y-axis shows the proportion of patients with relapse. The chart suggests a comparison between the two treatments in terms of relapse rates.*
FDA Label Image

Figure-7 (Figure Seven)

Figure-7 (Figure Seven)
This text provides data on the percentage of patients improved and the percentage improvement in pain from baseline. The table includes values ranging from 10 to 100 for the percentage of patients improved and from 50 to 290 for the percent improvement in pain from baseline. The medication mentioned is "Duloreine 60mg once daily."*
FDA Label Image

Figure-6 (Figure Six)

Figure-6 (Figure Six)
FDA Label Image

Figure-10 (Figure Ten)

Figure-10 (Figure Ten)
Percentage of Patients Improved: This data table shows the percentage of patients who experienced improvement in pain from baseline while undergoing treatment with Placebo and DULO 60/120 mg once daily. The graph indicates the percent improvement in pain from baseline according to the treatment groups.*
FDA Label Image

Figure-2 (Figure Two)

Figure-2 (Figure Two)
This text shows a chart depicting the proportion of patients experiencing a relapse over time from randomization. The x-axis represents the time in days, and the y-axis shows the proportion of patients with relapse. The chart provides a visual representation of how relapse rates change over time for the group being studied.*
FDA Label Image

Imprint (Imprint)

Imprint (Imprint)
FDA Label Image

Label-1 (Label 1)

Label-1 (Label 1)
This description provides information about a medication called Duloxetine in the form of delayed-release capsules. Each capsule contains 22.4 mg of duloxetine hydrochloride USP, equivalent to 20 mg of duloxetine. The medication guide should be dispensed to each patient. The usual dosage and storage instructions are included. The medication is distributed by ANI Pharmaceuticals, Inc.*
FDA Label Image

Label-2 (Label 2)

Label-2 (Label 2)
This text provides important information about Duloxetine Delayed-Release Capsules, USP in 30 mg strength. It includes details on the contents of each capsule, proper storage instructions, dosage information, and the manufacturer's and distributor's details. This medication guide must be dispensed to each patient by the pharmacist.*
FDA Label Image

Label-3 (Label 3)

Label-3 (Label 3)
This is a description of a medication called Duloxetine in the form of delayed-release capsules. Each capsule contains 67.3 mg of duloxetine hydrochloride USP equivalent to 60 mg duloxetine. The medication guide should be dispensed to each patient by the pharmacist. The usual dosage and storage instructions are provided, along with details of the manufacturer and distributor of the product. The medication is intended for prescription use only.*
FDA Label Image

Structure (Structure)

Structure (Structure)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.